Cost‐effectiveness of primary human papillomavirus triage approaches among vaccinated women in Norway: A model‐based analysis
International Journal of Cancer · 2024
DOI: 10.1002/ijc.34804 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2024. Verfasst von Allison Portnoy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Papillomavirus Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kreftforeningen.
Abstract (Originalsprache)
As Norway considers revising triage approaches following their first adolescent cohort with human papillomavirus (HPV) vaccination entering the cervical cancer screening program, we analyzed the health impact and cost‐effectiveness of alternative primary HPV triage approaches for women initiating cervical cancer screening in 2023. We used a multimodeling approach that captured HPV transmission and cervical carcinogenesis to evaluate the health benefits, harms and cost‐effectiveness of alternative extended genotyping and age‐based triage strategies under five‐yearly primary HPV testing (including the status‐quo screening strategy in Norway) for women born in 1998 (ie, age 25 in 2023). We examined 35 strategies that varied alternative groupings of high‐risk HPV genotypes (“high‐risk” genotypes; “medium‐risk” genotypes or “intermediate‐risk” genotypes), number and types of HPV included in each group, management of HPV‐positive women to direct colposcopy or active surveillance, wait time for re‐testing and age at which the HPV triage algorithm switched from less to more intensive strategies. Given the range of benchmarks for severity‐specific cost‐effectiveness thresholds in Norway, we found that the preferred strategy for vaccinated women aged 25 years in 2023 involved an age‐based switch from a less to more intensive follow‐up algorithm at age 30 or 35 years with HPV‐16/18 genotypes in the “high‐risk” group. The two potentially cost‐effective strategies could reduce the number of colposcopies compared to current guidelines and simultaneously improve health benefits. Using age to guide primary HPV triage, paired with selective HPV genotype and follow‐up time for re‐testing, could improve both the cervical cancer program effectiveness and efficiency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, USA.
- Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
- Department of Health Management and Health Economics, University of Oslo, Oslo, Norway.
- Section for Cervical Cancer Screening, Cancer Registry of Norway, Oslo, Norway.
ORCID-Profile: Allison Portnoy, Kine Pedersen, Ameli Tropé, Birgit Engesaeter, Emily A Burger
Förderung
- Kreftforeningen
Zitieren
APA
Portnoy, A., Pedersen, K., Sy, S., Tropé, A., Engesaeter, B., Kim, J. J., & Burger, E. A. (2024). Cost‐effectiveness of primary human papillomavirus triage approaches among vaccinated women in Norway: A model‐based analysis. International Journal of Cancer. https://doi.org/10.1002/ijc.34804
Vancouver
Portnoy A, Pedersen K, Sy S, Tropé A, Engesaeter B, Kim JJ, et al. Cost‐effectiveness of primary human papillomavirus triage approaches among vaccinated women in Norway: A model‐based analysis. International Journal of Cancer. 2024. doi:10.1002/ijc.34804
BibTeX
@article{Portnoy2024,
author = {Portnoy, Allison and Pedersen, Kine and Sy, Stephen and Tropé, Ameli and Engesaeter, Birgit and Kim, Jane J and Burger, Emily A},
title = {Cost‐effectiveness of primary human papillomavirus triage approaches among vaccinated women in Norway: A model‐based analysis},
journal = {International Journal of Cancer},
year = {2024},
doi = {10.1002/ijc.34804}
}
EUVIMED